D. E. Shaw & Co., Inc. Eli Lilly & CO Call Options Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

Call Options

25 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$772.14 - $960.02 $61.5 Million - $76.5 Million	79,700 Added 24.01%	411,700 $365 Million
Q2 2024 Aug 14, 2024	SELL	$724.87 - $909.04 $38.6 Million - $48.4 Million	-53,200 Reduced 13.81%	332,000 $301 Million
Q1 2024 May 15, 2024	BUY	$592.2 - $792.28 $21.3 Million - $28.4 Million	35,900 Added 10.28%	385,200 $300 Million
Q4 2023 Feb 14, 2024	BUY	$525.19 - $619.13 $42.8 Million - $50.4 Million	81,400 Added 30.38%	349,300 $204 Million
Q3 2023 Nov 14, 2023	BUY	$434.7 - $599.3 $32.2 Million - $44.4 Million	74,100 Added 38.24%	267,900 $144 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $43.4 Million - $58 Million	123,600 Added 176.07%	193,800 $90.9 Million
Q1 2023 May 15, 2023	SELL	$310.63 - $364.82 $6.21 Million - $7.3 Million	-20,000 Reduced 22.17%	70,200 $24.1 Million
Q4 2022 Feb 14, 2023	BUY	$321.55 - $374.67 $9.16 Million - $10.7 Million	28,500 Added 46.19%	90,200 $33 Million
Q3 2022 Nov 14, 2022	SELL	$296.48 - $337.87 $21.6 Million - $24.6 Million	-72,800 Reduced 54.13%	61,700 $20 Million
Q2 2022 Aug 15, 2022	BUY	$278.73 - $327.27 $6.83 Million - $8.02 Million	24,500 Added 22.27%	134,500 $43.6 Million
Q1 2022 May 16, 2022	BUY	$234.69 - $291.66 $2.35 Million - $2.92 Million	10,000 Added 10.0%	110,000 $31.5 Million
Q4 2021 Feb 14, 2022	BUY	$224.85 - $279.04 $8.99 Million - $11.2 Million	40,000 Added 66.67%	100,000 $27.6 Million
Q3 2021 Nov 15, 2021	BUY	$221.6 - $272.71 $4.43 Million - $5.45 Million	20,000 Added 50.0%	60,000 $13.9 Million
Q2 2021 Aug 16, 2021	BUY	$180.55 - $233.54 $5.42 Million - $7.01 Million	30,000 Added 300.0%	40,000 $9.18 Million
Q1 2021 May 17, 2021	SELL	$164.32 - $212.72 $4.27 Million - $5.53 Million	-26,000 Reduced 72.22%	10,000 $1.87 Million
Q4 2020 Feb 16, 2021	SELL	$130.46 - $172.63 $3.2 Million - $4.23 Million	-24,500 Reduced 40.5%	36,000 $6.08 Million
Q3 2020 Nov 16, 2020	SELL	$146.22 - $169.13 $7.06 Million - $8.17 Million	-48,300 Reduced 44.39%	60,500 $8.96 Million
Q2 2020 Aug 14, 2020	SELL	$136.42 - $164.18 $1.92 Million - $2.31 Million	-14,100 Reduced 11.47%	108,800 $17.9 Million
Q1 2020 May 15, 2020	SELL	$119.05 - $147.35 $2.99 Million - $3.7 Million	-25,100 Reduced 16.96%	122,900 $17 Million
Q4 2019 Feb 14, 2020	SELL	$106.92 - $132.43 $2.67 Million - $3.31 Million	-25,000 Reduced 14.45%	148,000 $19.5 Million
Q2 2019 Aug 14, 2019	SELL	$110.79 - $129.32 $54 Million - $63.1 Million	-487,700 Reduced 73.82%	173,000 $19.2 Million
Q1 2019 May 15, 2019	BUY	$111.31 - $131.02 $56.4 Million - $66.4 Million	506,700 Added 329.03%	660,700 $85.7 Million
Q4 2018 Feb 14, 2019	BUY	$105.9 - $118.64 $9.54 Million - $10.7 Million	90,100 Added 141.0%	154,000 $17.8 Million
Q3 2018 Nov 14, 2018	BUY	$85.86 - $107.31 $4.69 Million - $5.86 Million	54,600 Added 587.1%	63,900 $6.86 Million
Q2 2018 Aug 14, 2018	BUY	$75.7 - $86.88 $704,010 - $807,984	9,300 New	9,300 $794,000

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

751M

Call Options Held

8.27M

Put Options Held

10.5M

Lilly Endowment Inc Indianapolis, IN

96.9M
Shares

$77.1 Billion
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

73.8M
Shares

$58.7 Billion
1.2% of portfolio
Black Rock Inc. New York, NY

65.9M
Shares

$52.4 Billion
1.37% of portfolio
Pnc Financial Services Group, Inc. Pittsburgh, PA

51.4M
Shares

$40.9 Billion
29.2% of portfolio
State Street Corp Boston, MA

33.9M
Shares

$26.9 Billion
1.24% of portfolio

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account